BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29685955)

  • 1. Apigenin inhibits C5a-induced proliferation of human nasopharyngeal carcinoma cells through down-regulation of C5aR.
    Zhang Y; Cao Y; Zhang L; Feng C; Zhou G; Wen G
    Biosci Rep; 2018 May; 38(3):. PubMed ID: 29685955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C5a promotes the proliferation of human nasopharyngeal carcinoma cells through PCAF-mediated STAT3 acetylation.
    Cai K; Wan Y; Wang Z; Wang Y; Zhao X; Bao X
    Oncol Rep; 2014 Nov; 32(5):2260-6. PubMed ID: 25174320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C5a induces A549 cell proliferation of non-small cell lung cancer via GDF15 gene activation mediated by GCN5-dependent KLF5 acetylation.
    Zhao C; Li Y; Qiu W; He F; Zhang W; Zhao D; Zhang Z; Zhang E; Ma P; Liu Y; Ma L; Yang F; Wang Y; Shu Y
    Oncogene; 2018 Aug; 37(35):4821-4837. PubMed ID: 29773900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
    Nitta H; Wada Y; Kawano Y; Murakami Y; Irie A; Taniguchi K; Kikuchi K; Yamada G; Suzuki K; Honda J; Wilson-Morifuji M; Araki N; Eto M; Baba H; Imamura T
    Clin Cancer Res; 2013 Apr; 19(8):2004-13. PubMed ID: 23287562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the C5a-C5a receptor system on breast cancer progression and patient prognosis.
    Imamura T; Yamamoto-Ibusuki M; Sueta A; Kubo T; Irie A; Kikuchi K; Kariu T; Iwase H
    Breast Cancer; 2016 Nov; 23(6):876-885. PubMed ID: 26494574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesenchymal stem cells alleviate acute kidney injury by down-regulating C5a/C5aR pathway activation.
    Tang M; Zhang K; Li Y; He QH; Li GQ; Zheng QY; Zhang KQ
    Int Urol Nephrol; 2018 Aug; 50(8):1545-1553. PubMed ID: 29594894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C5aR is frequently expressed in metastatic renal cell carcinoma and plays a crucial role in cell invasion via the ERK and PI3 kinase pathways.
    Maeda Y; Kawano Y; Wada Y; Yatsuda J; Motoshima T; Murakami Y; Kikuchi K; Imamura T; Eto M
    Oncol Rep; 2015 Apr; 33(4):1844-50. PubMed ID: 25682807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent C5a and C5aR expression in dental pulp cells following stimulation with LTA and LPS.
    Liu M; Mu H; Peng W; Zhao L; Hu W; Jiang Z; Gao L; Cao X; Li N; Han J
    Int J Mol Med; 2019 Sep; 44(3):823-834. PubMed ID: 31257457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement 5a stimulates macrophage polarization and contributes to tumor metastases of colon cancer.
    Piao C; Zhang WM; Li TT; Zhang CC; Qiu S; Liu Y; Liu S; Jin M; Jia LX; Song WC; Du J
    Exp Cell Res; 2018 May; 366(2):127-138. PubMed ID: 29551360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C5a/C5aR pathway is essential for up-regulating SphK1 expression through p38-MAPK activation in acute liver failure.
    Lei YC; Lu CL; Chen L; Ge K; Yang LL; Li W; Wu YH
    World J Gastroenterol; 2016 Dec; 22(46):10148-10157. PubMed ID: 28028363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C5a/C5aR pathway accelerates renal ischemia-reperfusion injury by downregulating PGRN expression.
    Zhang K; Li GQ; He QH; Li Y; Tang M; Zheng QY; Xu GL; Zhang KQ
    Int Immunopharmacol; 2017 Dec; 53():17-23. PubMed ID: 29031143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement C5a/C5aR pathway potentiates the pathogenesis of gastric cancer by down-regulating p21 expression.
    Chen J; Li GQ; Zhang L; Tang M; Cao X; Xu GL; Wu YZ
    Cancer Lett; 2018 Jan; 412():30-36. PubMed ID: 29031586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. C5aR deficiency attenuates the breast cancer development via the p38/p21 axis.
    Chen J; Sun ZH; Chen LY; Xu F; Zhao YP; Li GQ; Tang M; Li Y; Zheng QY; Wang SF; Yang XH; Wu YZ; Xu GL
    Aging (Albany NY); 2020 Jul; 12(14):14285-14299. PubMed ID: 32669478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer C5a receptor expression and augmentation of cancer cell proliferation, invasion, and PD-L1 expression by C5a.
    Imamura R; Kitagawa S; Kubo T; Irie A; Kariu T; Yoneda M; Kamba T; Imamura T
    Prostate; 2021 Feb; 81(3):147-156. PubMed ID: 33368414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C5a receptor enhances hepatocellular carcinoma cell invasiveness via activating ERK1/2-mediated epithelial-mesenchymal transition.
    Hu WH; Hu Z; Shen X; Dong LY; Zhou WZ; Yu XX
    Exp Mol Pathol; 2016 Feb; 100(1):101-8. PubMed ID: 26475622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
    Gu H; Fisher AJ; Mickler EA; Duerson F; Cummings OW; Peters-Golden M; Twigg HL; Woodruff TM; Wilkes DS; Vittal R
    FASEB J; 2016 Jun; 30(6):2336-50. PubMed ID: 26956419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional identification of the stable transfection C5aR cell line Molt-4.
    Zhang C; Xu R; Wang J; Han G; Chen G; Wang R; Wei H; Shen B; Ma Y; Li Y
    Cell Mol Immunol; 2007 Dec; 4(6):461-5. PubMed ID: 18163958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling of the Complement Cleavage Product Anaphylatoxin C5a Through C5aR (CD88) Contributes to Pharmacological Hematopoietic Stem Cell Mobilization.
    Bujko K; Rzeszotek S; Hoehlig K; Yan J; Vater A; Ratajczak MZ
    Stem Cell Rev Rep; 2017 Dec; 13(6):793-800. PubMed ID: 28918528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-Time Imaging of Interactions of Neutrophils with Cryptococcus neoformans Demonstrates a Crucial Role of Complement C5a-C5aR Signaling.
    Sun D; Zhang M; Liu G; Wu H; Zhu X; Zhou H; Shi M
    Infect Immun; 2016 Jan; 84(1):216-29. PubMed ID: 26502909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C5a receptor (CD88) promotes motility and invasiveness of gastric cancer by activating RhoA.
    Kaida T; Nitta H; Kitano Y; Yamamura K; Arima K; Izumi D; Higashi T; Kurashige J; Imai K; Hayashi H; Iwatsuki M; Ishimoto T; Hashimoto D; Yamashita Y; Chikamoto A; Imanura T; Ishiko T; Beppu T; Baba H
    Oncotarget; 2016 Dec; 7(51):84798-84809. PubMed ID: 27756879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.